{{Drugbox
| verifiedrevid = 470611877
| IUPAC_name = 2-{4-[(1''Z'')-4-chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy}-''N,N''-dimethylethanamine
| image = Toremifene.svg
| width = 250
<!--Clinical data-->
| tradename = Fareston
| Drugs.com = {{drugs.com|monograph|fareston}}
| MedlinePlus = a608003
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = More than 99.5%
| metabolism =  
| elimination_half-life = 5 days
| excretion =  
<!--Identifiers-->
| IUPHAR_ligand = 4325
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 89778-26-7
| ATC_prefix = L02
| ATC_suffix = BA02
| ATC_supplemental =  
| PubChem = 3005573
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00539
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2275722
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7NFE54O27T
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08620
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9635
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1655
| PDB_ligand = T0R
<!--Chemical data-->
| C=26 | H=28 | Cl=1 | N=1 | O=1
| molecular_weight = 405.959 g/mol
| smiles = ClCCC(/c1ccccc1)=C(/c2ccc(OCCN(C)C)cc2)c3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XFCLJVABOIYOMF-QPLCGJKRSA-N
}}
{{Update|date=April 2017|reason=}}
'''Toremifene citrate''' ({{IPAc-en|ˈ|t|oʊ|r|ᵻ|m|ᵻ|f|i|n}}) is an oral [[selective estrogen receptor modulator]] (SERM) which helps oppose the actions of [[estrogen]] in the body. Licensed in the United States under the brand name '''Fareston''', toremifene citrate is [[Food and Drug Administration|FDA]]-approved for use in advanced ([[metastatic]]) [[breast cancer]]. It is also being evaluated for prevention of [[prostate cancer]] under the brand name '''Acapodene'''.<ref>Price N, Sartor O, Hutson T, Mariani S. Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. ''Clin Prostate Cancer'' 2005;3:211-4. {{PMID|15882476}}</ref>

In 2007 the pharmaceutical company [[Gtx inc|GTx, Inc]] was conducting two different phase 3 [[clinical trial]]s; First, a pivotal Phase clinical trial for the treatment of serious side effects of [[androgen deprivation therapy]] (ADT) (especially vertebral/spine fractures and [[hot flashes]], lipid profile, and [[gynecomastia]]) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade [[prostatic intraepithelial neoplasia]], or PIN. Results of these trials are expected by first quarter of 2008<ref>{{cite press release
| title = GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review   | publisher = GTx Inc. | date = 2007-07-12
| url = http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=1025420&highlight=   | accessdate = 2006-07-14 }}</ref>

An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009,<ref>{{cite press release
| title = GTx Announces Toremifene 80 mg NDA Accepted for Review by FDA | url = http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=1257471&highlight= }}</ref> and in Oct 2009 the FDA said they would need more clinical data, e.g. another phase III trial.<ref>{{cite web |url=http://www.genengnews.com/gen-news-highlights/gtx-and-ipsen-end-prostate-cancer-collaboration-due-to-costs-of-fda-requested-phase-iii-study/81244761/ |title=GTx and Ipsen End Prostate Cancer Collaboration due to Costs of FDA-Requested Phase III Study |date=2 Mar 2011 }}</ref>

==References==
{{Reflist|2}}


{{Estrogens and antiestrogens}}
{{Estrogen receptor modulators}}

[[Category:Organochlorides]]
[[Category:Phenol ethers]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Triphenylethylenes]]
[[Category:World Anti-Doping Agency prohibited substances]]


{{antineoplastic-drug-stub}}